What does this research mean for the field?

GLP-1 receptor agonists are not associated with significant differences in revascularization or amputation outcomes in individuals with diabetes and peripheral artery disease. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to evaluate the impact of glucagon-like peptide 1 receptor agonists on outcomes in peripheral arterial disease and diabetes.

February 19, 2026Diabetes Therapy1 citationsOpen Access

Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis

BEBeth ElliottUniversity of Surrey ETEllie TomlinsonUniversity of Surrey NDNirali DesaiKing's College Hospital

Key Points

The aim is to evaluate the impact of glucagon-like peptide 1 receptor agonists on outcomes in peripheral arterial disease and diabetes.
Conducted a meta-analysis of randomized trials
Included studies focused on GLP-1 receptor agonists
Examined outcomes like revascularization and amputation
No statistically significant differences observed in revascularization outcomes
No significant differences found in amputation rates among groups receiving GLP-1 RAs

Abstract

In this meta-analysis of randomized trials, GLP-1 RAs were not associated with statistically significant differences in revascularization or amputation outcomes in individuals with diabetes and PAD.

Perguntar à IA

Bookmark

View Full Paper